Blog

In the field of oncology, relapsed or refractory peripheral T-cell lymphoma (PTCL) and endocrine therapy resistance in HR-positive advanced breast cancer remain two major clinical challenges. It is in response to these significant unmet medical…

The treatment of advanced gastrointestinal stromal tumors (GIST) is a long and arduous race against genetic mutations. 💊 Patients typically follow a standard sequential treatment pathway: first-line imatinib, second-line sunitinib, and third-line regorafenib. ☹️ However,…

In the field of HIV antiviral therapy, “simplification” and “potency” have long been the two enduring goals that define the gold standard in HIV treatment. A prime example that perfectly integrates both is Biktarvy®—a single-tablet…

When should you take Avatrombopag Maleate (Qinganxin)? ❗ Platelets, these tiny components in the blood, play a crucial role in the body’s clotting process. When their numbers drop significantly, the body is left without an…

In advanced colorectal cancer, the exhaustion of first- and second-line standard chemotherapies and targeted therapies often results in a later-line treatment bottleneck, characterized by renewed disease progression and severely limited therapeutic options. This created an…

When it comes to domestic generic drugs, many people may instinctively associate them with stereotypes such as “cheap substitutes,” “second-choice options,” or “compromised efficacy.” However, Saibeixin Pazopanib Tablets stand as a clear example that challenges…

For many patients with advanced renal cell carcinoma, breast cancer, or neuroendocrine tumors, targeted therapy represents a critical source of hope—helping to extend survival and control disease progression. 💰 Yet before that hope can be…

On March 8, 2023, China’s National Medical Products Administration (NMPA) announced a significant glumetinib approval—the conditional market authorization of the Class 1 innovative drug Glumetinib Tablets (brand name: Hai Yi Tan®), developed by Shanghai HaiHe Pharmaceutical.…

Nasopharyngeal carcinoma (NPC) was once regarded as a mysterious regional disease, as its incidence was exceptionally high in southern China, Southeast Asia, and other regions—particularly in Guangdong Province, China—leading to its historical designation as “Guangdong…

In the field of autoimmune disease treatment, 2021 marked a significant milestone—the world’s first-in-class dual-target biologic drug Telitacicept (brand name: Tai Ai®), independently developed in China, was officially approved for marketing for the treatment of…

IgA nephropathy is the most common primary glomerular disease in China, accounting for approximately 40%–50% of all primary glomerulonephritis cases. For many years, the treatment of IgA nephropathy has primarily relied on supportive therapies, especially…